Business Wire

W Green Pay (WGP) - The Global Solution to Greenhouse Gas (GHG) Reduction

Share

W-Foundation (www.gcrfund.org/en/), the philanthropic foundation behind HOOXI campaign, Global Nature Conservation Campaign, introduces W Green Pay (WGP), the ERC20-compliant blockchain, to reward HOOXI app users for their Greenhouse Gas (GHG) reduction efforts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180530005620/en/

(Graphic: W-Foundation)

(Graphic: W-Foundation)

Korean government officials attended and shared congratulatory messages at the “Nation-wide Public Movement to Reduce GHG Emission (HOOXI Campaign)” Declaration and Committee Inauguration Ceremony held at National Assembly in December 2017 and April 2018: Kim, Eunkyung (Minister, Ministry of Environment), Kim, Hyunmee (Minister, Ministry of Land, Infrastructure, and Transport), Jeong, Segyun (Chairman, National Assembly), Choo, Miae (Representative Member, Democratic Party – the ruling party), Im, Jongseong (Member, National Assembly), and many more.

Sustainable business model: Globally first to reward individuals in carbon market

HOOXI app will aggregate the GHG reduction data of individuals, for which Korean government will allocate NEPs (National Emission Permit: trades at approximately US$20 for 1 ton). With revenue from the allocated NEPs traded at the market, HOOXI app will fund its operations and the ongoing market purchase of WGP to reward users.

HOOXI app: Gamification features with instantaneous rewards (WGP)

HOOXI app offers a variety of functional advantages.

First, HOOXI app is a ground-breaking platform digitizing public participation and rewards for GHG reduction efforts.

Second, HOOXI app is a mobile app-based environmental encyclopedia. HOOXI app provides easily executable ways to reduce GHG in everyday life, and information on environmental impacts driven by user participation.

Third, HOOXI app uses artificial intelligence (AI) to analyze the profile of each user and customize missions for their lifestyle, age, gender, occupation. Based on these analyzed information, tailored daily, weekly and monthly GHG reduction missions will be sent to users.

Fourth, HOOXI app incentivizes users through its gamification features. HOOXI app can track users’ daily exercise stats as Fitbit does and suggest location-based missions as Pokémon Go’s does. Based on their completed mission points, users can track their ranks and compete within and between their groups, i.e. friends, companies, and the entire country.

Fifth, think of the likes on your Instagram posts — we are constantly endeavoring to achieve and be rewarded instantaneously. With its social networking service features, HOOXI app encourages users to get on the app daily to earn rewards.

Using WGP: Shopping, cashback and more

Users can use WGP tokens in different channels. W-Foundation’s HOOXI mall and partnered-online and offline retail stores will accept WGP for payment. WGP-affiliated credit card with Korean commercial banks will also be launched, with WGP as a payback system for credit card users.

W-Foundation continues to work on HOOXI app’s development as well as WGP’s utility. “As more users join, HOOXI app will extract a greater value from the carbon market and enhance WGP’s value and liquidity to its holders,” said Youree Lee, CEO of W-Foundation.

Subscribe on W Green Pay (WGP) website ( www.wpay.sg ), for promotions and exclusive updates.

Contact information

Media Enquiries
W-Foundation
Michael Lee
michael@wfoundation.kr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu